Lometrexol

N/A

Report date: 2022/11/25 16:34:12
NME

Base Information

Drug NameLometrexol
Drug Alias Namelometrexol洛美曲索lometrexolum洛美曲沙DDATHF-B +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGAR transformylase inhibitors
TargetsGAR transformylase
Therapy Area/IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteTularik Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsLung Neoplasms

Other Information

ATC CodeN/A
Related LinksKEGG